United Therapeutics Corporation Excess Tax Benefit from Share-based Compensation, Operating Activities
United Therapeutics Corporation (UTHR) reported Excess Tax Benefit from Share-based Compensation, Operating Activities of $5.90 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-02-27.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities · last filed 2019-02-27
- United Therapeutics Corporation excess tax benefit from share-based compensation, operating activities for the quarter ending 2016-12-31 was $1.30M, a 78.33% decline year-over-year.
- United Therapeutics Corporation excess tax benefit from share-based compensation, operating activities for the quarter ending 2016-09-30 was $1.10M, a 86.08% decline year-over-year.
- United Therapeutics Corporation excess tax benefit from share-based compensation, operating activities for the quarter ending 2016-06-30 was $1.40M, a 90.54% decline year-over-year.
- United Therapeutics Corporation excess tax benefit from share-based compensation, operating activities for the quarter ending 2016-03-31 was $2.10M, a 75.86% decline year-over-year.
- United Therapeutics Corporation excess tax benefit from share-based compensation, operating activities for fiscal 2016 was $5.90M, a 84.22% decline from fiscal 2015.
- United Therapeutics Corporation excess tax benefit from share-based compensation, operating activities for fiscal 2015 was $37.40M, a 21.43% increase from fiscal 2014.
- United Therapeutics Corporation excess tax benefit from share-based compensation, operating activities for fiscal 2014 was $30.80M, a 231.22% increase from fiscal 2013.
- United Therapeutics Corporation excess tax benefit from share-based compensation, operating activities for fiscal 2013 was $9.30M, a 204.49% increase from fiscal 2012.
| Period end | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month as first filed | Excess Tax Benefit from Share-based Compensation, Operating Activities 6 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 6 month as first filed | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month as first filed | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $2.40M derived: sum of 2 quarters · filed 2019-02-27 | $3.80M derived: sum of 3 quarters · filed 2019-02-27 | $5.90M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $2.50M derived: sum of 2 quarters · filed 2017-10-25 | $4.60M 10-Q · filed 2017-10-25 | $10.60M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $3.50M 10-Q · filed 2017-07-27 | $9.50M derived: sum of 3 quarters · filed 2018-02-21 | $17.40M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | $2.10M 10-Q · filed 2017-04-26 | $8.10M derived: sum of 2 quarters · filed 2018-02-21 | $16.00M derived: sum of 3 quarters · filed 2018-02-21 | $30.80M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $13.90M derived: sum of 2 quarters · filed 2018-02-21 | $28.70M derived: sum of 3 quarters · filed 2018-02-21 | $37.40M 10-K · filed 2018-02-21 | $37.43M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $7.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $22.70M derived: sum of 2 quarters · filed 2016-10-27 | $31.40M 10-Q · filed 2016-10-27 | $31.38M 10-Q · filed 2015-10-27 | $39.02M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-06-30 | $14.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $23.50M 10-Q · filed 2016-07-28 | $23.49M 10-Q · filed 2015-07-28 | $31.12M derived: sum of 3 quarters · filed 2017-02-22 | $40.26M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-03-31 | $8.70M 10-Q · filed 2016-04-28 | $8.72M 10-Q · filed 2015-04-28 | $16.32M derived: sum of 2 quarters · filed 2017-02-22 | $25.46M derived: sum of 3 quarters · filed 2017-02-22 | $33.89M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | $7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $16.76M derived: sum of 2 quarters · filed 2017-02-22 | $25.19M derived: sum of 3 quarters · filed 2017-02-22 | $30.80M 10-K · filed 2017-02-22 | $30.84M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $9.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $17.58M derived: sum of 2 quarters · filed 2015-10-27 | $23.18M 10-Q · filed 2015-10-27 | $26.68M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $8.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28 | $14.04M 10-Q · filed 2015-07-28 | $17.53M derived: sum of 3 quarters · filed 2016-02-25 | $20.70M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $5.61M 10-Q · filed 2015-04-28 | $9.10M derived: sum of 2 quarters · filed 2016-02-25 | $12.27M derived: sum of 3 quarters · filed 2016-02-25 | $13.94M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $3.49M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $6.67M derived: sum of 2 quarters · filed 2016-02-25 | $8.34M derived: sum of 3 quarters · filed 2016-02-25 | $9.30M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $3.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $4.84M derived: sum of 2 quarters · filed 2014-10-28 | $5.81M 10-Q · filed 2014-10-28 | $6.78M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $2.63M 10-Q · filed 2014-07-29 | $3.60M derived: sum of 3 quarters · filed 2015-02-24 | $5.00M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $962.00K 10-Q · filed 2014-04-29 | $1.93M derived: sum of 2 quarters · filed 2015-02-24 | $3.33M derived: sum of 3 quarters · filed 2015-02-24 | $3.70M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | $970.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $2.37M derived: sum of 2 quarters · filed 2015-02-24 | $2.74M derived: sum of 3 quarters · filed 2015-02-24 | $3.05M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $1.77M derived: sum of 2 quarters · filed 2013-10-29 | $2.08M 10-Q · filed 2013-10-29 | $6.95M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $366.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $684.00K 10-Q · filed 2013-07-25 | $5.54M derived: sum of 3 quarters · filed 2014-02-25 | $5.74M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $318.00K 10-Q · filed 2013-04-25 | $5.18M derived: sum of 2 quarters · filed 2014-02-25 | $5.38M derived: sum of 3 quarters · filed 2014-02-25 | $7.69M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $5.06M derived: sum of 2 quarters · filed 2014-02-25 | $7.37M derived: sum of 3 quarters · filed 2014-02-25 | $11.35M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $197.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $2.51M derived: sum of 2 quarters · filed 2012-11-01 | $6.49M 10-Q · filed 2012-11-01 | $11.59M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $6.29M 10-Q · filed 2012-07-26 | $11.39M derived: sum of 3 quarters · filed 2013-02-26 | $13.76M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $3.98M 10-Q · filed 2012-04-26 | $9.08M derived: sum of 2 quarters · filed 2013-02-26 | $11.45M derived: sum of 3 quarters · filed 2013-02-26 | $17.04M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $7.47M derived: sum of 2 quarters · filed 2013-02-26 | $13.07M derived: sum of 3 quarters · filed 2013-02-26 | $23.83M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $2.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $7.97M derived: sum of 2 quarters · filed 2011-10-27 | $18.73M 10-Q · filed 2011-10-27 | $20.42M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-06-30 | $5.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $16.36M 10-Q · filed 2011-07-28 | $18.05M derived: sum of 3 quarters · filed 2012-02-28 | $19.17M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-03-31 | $10.76M 10-Q · filed 2011-04-28 | $12.46M derived: sum of 2 quarters · filed 2012-02-28 | $13.57M derived: sum of 3 quarters · filed 2012-02-28 | |||||
| 2009-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $2.81M derived: sum of 2 quarters · filed 2012-02-28 | $4.41M 10-K · filed 2012-02-28 | |||||
| 2009-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $2.71M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $1.59M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | $21.09M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |